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Abstract
OBJECTIVE: This study used gated myocardial per-
fusion imaging (G-MPI) to assess the clinical value
of Xinmailong injection in chronic congestive heart
failure (CHF).
METHODS: A total of 102 CHF patients were ran-
domly divided into the control group (n=51) and
the Xinmailong group (n=51). Patients in the con-
trol group were routinely treated. Patients in the
Xinmailong group were additionally treated with
Xinmailong injection in addition to routine treat-
ment. Before and 3 months after treatment, G-MPI
was used to determine changes in the left ventricu-
lar ejection fraction (LVEF), left ventricular end-dia-
stolic volume (LVEDV) and left ventricular end-sys-
tolic volume (LVESV). Fourteen days after treat-
ment, changes in plasma brain natriuretic peptide
(BNP) levels were determined.
RESULTS: Before treatment, there were no signifi-
cant differences in LVEF, LVEDV, LVESV, and BNP lev-
els between the two groups (all P>0.05). After treat-
ment, LVEDV, LVESV, and BNP levels were signifi-
cantly lower, and LVEF was significantly higher in
the Xinmailong group than in the control group (all
P<0.05).
CONCLUSION: Additional use of Xinmailong injec-
tion in addition to routine treatment improves car-
diac function of CHF patients. Because of the safety
and effectiveness of Xinmailong injection, this ther-
apy should be promoted.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Chronic congestive heart failure (CHF) is a syndrome
in which cardiac structural or functional diseases cause
myocardial damage, a large ventricular load, weakened
ventricular diastolic force, and reduced ventricular ejec-
tion volume. Consequently, metabolic requirements of
the body cannot be met. CHF is a commonly and fre-
quently encountered disease, and is the terminal stage
of cardiac disease, with extremely high mortality. Epide-
miological data have shown that for CHF, the hospital-
ization rate accounts for 20% and mortality for 40%
of cardiovascular diseases at the same stage, and its sur-
vival rate is similar to that of tumors.1,2 There is an in-
crease of 200 000 CHF patients every year worldwide.3
The incidence of CHF is increasing in China,4 and its
incidence among older people is as high as 1.3% .5
Some CHF patients are treated with digitalis, ethyl ni-
trate, β receptor inhibitors, and angiotensin-converting
enzyme inhibitors, but there is no ideal cure. There-
fore, the clinical symptoms and prognosis of CHF
need to be further improved.
Compound nucleoside bases and conjugated amino ac-
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ids, which are two effective ingredients of Xinmailong
injection extracted from cockroaches, can dilate the
coronary artery, antagonize activation of neuroendo-
crine, increase blood supply to cardiac muscle, im-
prove cardiac function, and antagonize ventricular re-
structuring.6
In this study, we examined the effect of Xinmailong in-
jection while applying routine treatment in CHF pa-
tients by strengthening the heart and inducing urina-
tion. We used gated myocardial perfusion imaging
(G-MPI) to determine changes in left ventricular ejec-
tion fraction (LVEF), left ventricular end-diastolic vol-
ume (LVEDV), left ventricular end-systolic volume
(LVESV), and brain natriuretic peptide (BNP) levels
before and after treatment to assess the curative effect
of Xinmailong injection.
MATERIALS ANDMETHODS
Patients
We studied 102 CHF inpatients from the medical de-
partment of the heart, The Third Hospital of Hebei
Medical University from April 2011 to October
2013.
Inclusion criteria
All patients with Ⅱ-Ⅳ cardiac function according to
the guide for diagnosing and treating CHF (compiled
by the cardiovascular disease branch of the China Med-
ical Association, 2007 edition)7 were included.
Exclusion criteria
Patients with the following conditions were excluded:
hypotension, acute left heart failure, acute myocardial
infarction, severe valvulopathy, hypertrophic obstruc-
tive cardiomyopathy, pulmonary heart disease, severe
insufficiency of the liver and kidney, and those who
were sensitive to Xinmailong.
Modeling and grouping
A total of 102 inpatients were randomly divided into
the control group (n=51; serial number: 1-51) and the
Xinmailong group (n=51; serial number: 52-102). Pa-
tients in the control group were routinely treated. Pa-
tients in the Xinmailong group were additionally treat-
ed with Xinmailong injection in addition toroutine
treatment. In the Xinmailong group, there were 33 men
and 18 women, aged 57-73 years [mean, (65±7) years].
In the control group, there were 35 men and 16 wom-
en, aged 57-75 years [mean, (66±9) years]. There were
no significant differences in sex, age, hyperlipidemia,
diabetes, and hypertension between the two groups (P>
0.05, Table 1). This research was approved by the ethi-
cal committee of The Third hospital of Hebei Medical
University, and all of the patients signed a consent
form.
Methods
Therapy: patients in both groups were treated with fu-
rosemide (Zhaohui Pharmaceutical Co., Ltd., Shang-
hai, China), digoxin (Xinyi Pharmaceutical Co., Ltd.,
Shanghai, China), and lotensin, an angiotensin inver-
tase inhibitor (Nuohua Pharmaceutical Co., Ltd., Bei-
jing, China). In addition to routine treatment, patients
in the Xinmailong group were additionally treated
with an intravenous drip of Xinmailong injection (ap-
proval number: Z20060443; Tengchong Pharmaceuti-
cal Company, Yunnan, China) at a concentration of
5 mg/kg each time, twice a day, with an interval of
more than 6 h between each time, for 14 consecutive
days. These patients were also administered 5% glucose
injection or 200 mL of 9% NaCl injection with a drip
speed of 20-40 drops per min. Patients were treated for
the first time with Xinmailong injection if a skin test
was negative.
Determination of curative effects
Fourteen days after treatment, curative effects were as-
sessed in both groups. Effectiveness was defined as clin-
ical symptoms that were obviously improved and cardi-
ac function was ameliorated to one class. Ineffective-
ness was defined as no obvious improvement in clinical
symptoms, cardiac function was ameliorated to less
than one class, or heart failure was aggravated or even
death occurred.
Use of G-MPI
Before and 3 months after treatment in all of the pa-
tients, G-MPI was used to determine parameters of left
ventricular function with an Infinia Hawkeye double
probe single-photon emission computed tomography
(SPECT) instrument (GE Co., Fairfield, CT, USA)
and collimator with parallel holes, low energy, and
high resolution.
G-MPI was used 1.5 h after intravenous injection of
111-740 MBq99 Tcm-MIBI. The probe was obliquely
moved 45° from the right front to the left rear, and ro-
tated in a clockwise direction 180° to collect eight im-
ages every cardiac cycle, with a 64×64 matrix. Images
were analyzed with the Xeleris Functional Imaging
Workstation (GE Co., Fairfield, CT, USA), and origi-
nal images were restructured with filtering counter-pro-
jection. After restructuring, images of the horizontal
long axis, vertical long axis, and short axis were dis-
played. Based on three-dimensional restructuring,
quantitative gated SPECT (GE Co., Fairfield, CT,
USA) was used to analyze and calculate the left ventric-
ular functional parameters of left ventricular ejection
fraction (LVEF), left ventricular end-diastolic volume
(LVEDV), left ventricular end-systolic volume (LVESV).
Determination of plasma BNP levels
A BNP kit and the Triage BNP analyzer (Biosite Diag-
nostics Inc., San Diego, CA, USA) were used accord-
ing to themanufacturer's instructions. A volumeof 2 mL
of venous blood was extracted from all of the patients
before treatment and 14 days after treatment. Blood
samples were added to a test tube with anticoagulant
and it was evenly mixed. After a test plate had been
placed under room temperature for 15 min, a tube was
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used to extract blood samples and drip them onto the
test plate. Fifteen minutes later, the test plate automati-
cally displayed the test result.
Statistical analysis
Data are expressed by mean±standard deviation ( xˉ ±s).
The t-test was used for comparison before and after
treatment in the two groups, and for comparison be-
tween the two groups. The χ2 test was used for enumer-
ation data. P<0.05 was considered statistically signifi-
cant. SPSS 16.0 software (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis.
RESULTS
This study was conducted as follows (Figure 1). One
hundred and two CHF patients were recruited and di-
vided into 2 groups.
Comparison of baseline data between the two groups
There were no significant differences in baseline data
between the two groups (Table 1).
Comparison of curative effects between the two
groups
Treatment was effective in 46 patients and ineffective
in five patients, with a total efficacy rate of 90.2% in
the Xinmailong group. Treatment was effective in 34
patients and ineffective in 17 patients, with a total effi-
cacy rate of 66.7% in the control group. The Xin-
mailong group had a significantly better curative effect
than the control group (P<0.05, Table 2).
The CHF patients were randomly
divided into 2 groups (n=102）
Control group (n=51) Xinmailong group (n=51)
LVEF, LVEDV, LVESV and
BNP are determined with G-
MPI before treatment (n=51)
LVEF, LVEDV, LVESV and BNP
are determined with G-MPI before
treatment (n=51)
Treated with routine drug (n=51) Treated with routine drug andXinmailong (n=51)
14 days after treatment, BNP
is determined. 3 months after
treatment, G-MPI is used to
determine LEVF, LVEDV and
LVESV (n=51)
14 days after treatment, BNP is
determined. 3 months after
treatment, G-MPI is used to
determine LVEF, LVEDV and
LVESV (n=51)
Conclusion on data processing and
statistic analysis (n=102)
Figure 1 Diagram of the test procedure
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume;
BNP: brain natriuretic peptide.
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Comparison of LVEF, LVEDV, LVESV, and BNP
between the two groups
There were no significant differences in LVEF,
LVEDV, LVESV, and BNP levels before treatment be-
tween the two groups (P>0.05, Table 3). However,
LVEDV, LVESV, and BNP levels were significantly
lower, and LVEF was significantly higher after treat-
ment in the Xinmailong group compared with the con-
trol group (all P<0.01).
DISCUSSION
Currently, treating CHF includes eliminating
life-threatening factors, regulating metabolic mecha-
nisms, antagonizing excessive activation of neurohu-
moral factors, and obstructing and delaying myocardial
restructuring. Besides alleviating clinical symptoms,
CHF patients should strive to enhance the tolerable
amount of exercise, improve their quality of life, and re-
duce mortality.8 Drugs currently used by patients with
heart failure include angiotensin invertase inhibitors,
angiotensin receptor inhibitors, β receptor inhibitors,
aldehyde ketone receptor antagonists, diuretics, vasodi-
lators, and positive inotropic drugs, such as digitalis,
dobutamine, and milrinone. These drugs can improve
clinical symptoms, but increase myocardial oxygen con-
sumption, induce arrhythmia, and even increase mor-
tality.9
The developer in G-MPI can be extracted by active mi-
tochondria of myocardial cells, reflecting metabolism
and activation of normal myocardial cells. When myo-
cardial perfusion is obtained, LVEDV, LVESV, and
LVEF can simultaneously be obtained, representing pa-
rameters of left ventricular function and activity of the
local heart wall. G-MPI is a reliable method for assess-
ing the structure and function of the heart.
In our study, G-MPI was applied to assess the curative
effect of Xinmailong injection on CHF. We found that
clinical symptoms in the Xinmailong group improved
in 90.2% of patients, which was significantly better
than that with only routine treatment. LVEDV and
LVESV in the Xinmailong group were significantly
lower than those in the control group. LVEF in the
Xinmailong group was significantly higher than that in
the control group. These results indicated that improve-
ment of cardiac function in the Xinmailong group was
better than that in the control group. The mechanism
involved is that Xinmailong injection contains nucleo-
sides, compound amino acids, and polypeptides, which
accelerate calcium flow into myocardial cells to smooth-
ly and persistently strengthen myocardial contractive
power.10,11 These components of Xinmailong injection
can also increase calcitonin gene-related peptide con-
tent in plasma, leading to a decrease endothelin secre-
tion and inhibition of activation of nervous endo-
crine.12 In addition, these factors can dilate the renal ar-
Group
Control
Xinmailong
t
P value
n
51
51
-
-
LVEDV (mL)
Before
treatment
119±36
121±39
0.2828
>0.05
After
treatment
104±20
91±18a
3.4060
<0.01
LVESV (mL)
Before
treatment
73±28
75±26
0.3131
>0.05
After
treatment
58±22
43±18a
3.9250
<0.01
LVEF (%)
Before
treatment
37±3
37±3.5
1.1608
>0.05
After
treatment
48±3
53±3a
7.5650
<0.01
BNP (pg/mL)
Before
treatment
1706±117
1690±115
0.7279
>0.05
After
treatment
586±53
479±44a
11.1402
<0.01
Table 3 Comparison of LVEF, LVEDV, LVESV, and BNP levels between the two groups ( xˉ ±s)
Notes: patients in the control group were routinely treated, and those in the Xinmailong group were additionally treated with Xinmailong
on the basis of routine treatment. LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ven-
tricular end-systolic volume; BNP: brain natriuretic peptide. aP<0.01, compared with data after treatment in the control group.
Group
Control
Xinmailong
P value
n
51
51
-
Male/female（n）
35/16
33/18
>0.05
Age (years)
66±9
65±7
>0.05
Hyperlipemia [n (%)]
26（50.98）
25 (49.02)
>0.05
Diabetes [n (%)]
19 (37.25)
20 (39.22)
>0.05
Hypertension [n (%)]
18 (35.29)
19 (37.25)
>0.05
Table 1 Comparison of baseline data between the two groups ( xˉ ±s)
Notes: patients in the control group were routinely treated and those in the Xinmailong group were additionally treated with Xinmailong
in addition to routine treatment.
Group
Control
Xinmailong
n
51
51
Effectiveness (n)
34
46
Ineffectiveness (n)
17
5
Total effective rate (%)
66.7
90.2
Table 2 Comparison of the curative effect between the two groups
Notes: patients in the control group were routinely treated and those in the Xinmailong group were additionally treated with Xinmailong
on the basis of routine treatment.
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tery and improve microcirculation in the kidney to in-
duce urination, alleviate the cardiac load of CHF pa-
tients, and ameliorate blood stasis in the lung.13-15
Therefore, the curative effect of Xinmailong injection
on CHF is produced by strengthening myocardial con-
tractive power, inducing urination, dilating blood ves-
sels, and regulating endocrine and humoral factors.
Qilin et al 16 found that Xinmailong further enhances
cardiac function in patients with heart failure caused
by acute myocardial infarction, and reduces high sensi-
tivity-C reactive protein and N terminal pro-brain na-
triuretic peptide levels, improving the prognosis. Xin-
gwen and others17,18 have discovered that Xinmailong
injection remarkably improves right ventricular systolic
and diastolic function in patients with pulmonary
heart disease, and its curative effect is better than that
of routine treatment. Their results are similar to our
current findings.
BNP is a natural hormone with biological activity and
is synthesized by myocardial cells. Plasma BNP concen-
trations, a quantitative marker of heart failure, objec-
tively reflect the extent of heart failure and are closely
related to the prognosis of heart failure. Every increase
in BNP levels by 100 ng/L in CHF patients indicates
an increase in the risk of death by 35% .19 The guide
compiled by the European Heart Disease Association
in 2010 stresses that an increase in BNP levels is impor-
tant for diagnosing heart failure, and for the first time
points out a strategy for diagnosing heart failure with
symptoms. Using dynamic monitoring of BNP levels
to direct diagnosis and treatment of heart failure can re-
duce mortality and the re-hospitalization rate owing to
deterioration of heart failure.20 In our study, plasma
BNP levels in the Xinmailong group were significantly
lower than those in the control group after treatment.
This finding further indicates that Xinmailong injec-
tion improves clinical symptoms and the prognosis of
CHF patients.
In summary, Xinmailong injection can be used to effec-
tively treat CHF. Because of the small amount of sam-
ples and short time of observation in our study, further
studies are required to determine whether Xinmailong
injection improves the prognosis of CHF patients.
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